No Carolina / NY / Florida
Ph: 561.316.3330

No Carolina | NY | Florida

Fresenius Medical Care North America Announces 3 New Key Appointments

Editor: What To Know

  • “These individuals will help us continue to be the leader in value based care and transforming kidney care models that slow disease progression, while improving home dialysis and transplantation rates, clinical quality, and information technology to enhance experiences and affordability for the benefit of employees, physician partners, payors, and most importantly, our patients.
  • In her new role as Chief Nursing Officer, Belmonte will lead efforts to ensure the delivery of superior clinical care at every step of the renal care continuum, while also supporting the clinical professionals that make up patient care teams by overseeing career advancement opportunities.
  •  “Under their leadership in nursing care, health information technology, and organ transplantation, we will continue to drive innovation, expertise, and credibility that will enhance our ability to provide the highest quality of innovative and holistic care.

Fresenius Medical Care North America (FMCNA), the nation’s leading provider of kidney care products and services, announced three key clinical leadership appointments to help drive priorities, including improving patient outcomes, adopting connected health technologies to support home dialysis, and increasing access to transplant.

Kathleen Belmonte has been named Chief Nursing Officer and Senior Vice President of Clinical Services of Fresenius Kidney Care, the dialysis services division of FMCNA; Dr. Benjamin Hippen has been named Senior Vice President and Head of Transplant Medicine as part of the Global Medical Office senior leadership team; Dr. Shelly Nash has been appointed Senior Vice President and Chief Medical Information Officer for FMCNA.

“We welcome these exceptional clinical leaders who bring many years of deep experience working both inside and outside our company,” said Bill Valle, Chief Executive Officer, FMCNA. “These individuals will help us continue to be the leader in value based care and transforming kidney care models that slow disease progression, while improving home dialysis and transplantation rates, clinical quality, and information technology to enhance experiences and affordability for the benefit of employees, physician partners, payors, and most importantly, our patients.”

In her new role as Chief Nursing Officer, Belmonte will lead efforts to ensure the delivery of superior clinical care at every step of the renal care continuum, while also supporting the clinical professionals that make up patient care teams by overseeing career advancement opportunities. Belmonte continues to serve a critical role during the COVID-19 pandemic, implementing new policies and procedures during an unparalleled time and spearheading the vaccine rollout across Fresenius Kidney Care clinics nationwide. Belmonte has also exhibited leadership on new protocols to improve transplant referrals and waitlist management.

As Senior Vice President and Head of Transplant Medicine, another new role at Fresenius Medical Care, Dr. Hippen will lead the company’s efforts to expand access to and understanding of transplant medicine as a critical component of its patient-centric mission. Dr. Hippen extends his existing longstanding relationship with Fresenius Medical Care and brings with him more than 15 years of experience as a general and transplant nephrologist and practicing physician. He has also served as medical director of both a large in-center dialysis facility and large home therapies unit.

Appointed as Senior Vice President and Chief Medical Information Officer for FMCNA, Dr. Nash will be responsible for ensuring the seamless communication between clinical services and information technology – a critical component in our ability to provide best-in-class and life-sustaining care to patients. Dr. Nash joins us at a critical point as connected health solutions have evolved from being an emerging technology to something relied on to safely provide care. Dr. Nash previously served in a similar role for AdventHealth as Vice President and Chief Medical Information Officer & Chief of Quality Physician Enterprise.

“This expansion of our executive team underscores our commitment to improving patient outcomes on a global scale by acknowledging new leadership capabilities needed in the company,” said Dr. Franklin W. Maddux, Global Chief Medical Officer for Fresenius Medical Care. “Under their leadership in nursing care, health information technology, and organ transplantation, we will continue to drive innovation, expertise, and credibility that will enhance our ability to provide the highest quality of innovative and holistic care.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Recent News

CV Societies Propel Plans Forward for a New Board of Cardiovascular Medicine

“The open comment period is the time for cardiovascular physicians, allies in other medical specialties, patients, and others to make their voices heard on why an independent CV Board is the best path for cardiologists to stay up-to-date on best practices and evidence-based care, ensuring patients receive the best possible care,” said Jeffrey Kuvin, MD, president of the proposed Board’s new Board of Directors. “The field of cardiovascular medicine has evolved dramatically over the past few decades; now is the right time to develop an independent cardiovascular Board.”

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."

Sedana Medical Completes Patient Recruitment for INSPiRE-ICU 1 Clinical Trial in the US

Peter Sackey further elaborated: "Once the 30-day follow-up of all patients is complete, we will enter into an intense phase of final monitoring, data cleaning and transfer to our statistician team for analysis. In parallel, the long-term outcomes at 3 and 6 months will be collected centrally by the Critical Illness, Brain Dysfunction, and Survivorship team at Vanderbilt Medical Center. With this parallel approach, we expect topline results in the autumn of this year and a swift regulatory submission in Q1, 2025".

Health / Lifestyle

Articles of Interest

Stay Connected

spot_img

About Medical Device News Magazine

About Medical Device News Magazine. A digital publication founded in 2008 located in the United States. The publication is one of the industry’s leading sources of medical device and biotech industry updates. Medical Device News Magazine is easily accessible 24/7/365 and is a fast 1, 2, 3 easy read! Our purpose is...

By using this website you agree to accept Medical Device News Magazine Privacy Policy